M&A Deal Summary

Shire Acquires Baxalta

On January 11, 2016, Shire acquired life science company Baxalta for 32.0B USD

Acquisition Highlights
  • This is Shire’s 15th transaction in the Life Science sector.
  • This is Shire’s largest (disclosed) transaction.
  • This is Shire’s 13th transaction in the United States.
  • This is Shire’s 1st transaction in Illinois.

M&A Deal Summary
Date 2016-01-11
Target Baxalta
Sector Life Science
Buyer(s) Shire
Deal Type Merger
Deal Value 32.0B USD
Advisor(s) Goldman Sachs
Citi (Financial)
Kirkland & Ellis
Jones Day (Legal)

Target

Baxalta

Deerfield, Illinois, United States
Entrance to Baxalta office in Milford, Massachusetts.
Entrance to Baxalta office in Milford, Massachusetts.
Baxalta Incorporated is a global biopharmaceutical company developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology.

Search 201,771 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Shire

Dublin, Ireland
Category Company
Founded 1986
Sector Life Science
Employees5,548
Revenue 6.4B USD (2015)
DESCRIPTION

Shire plc is a global specialty biopharmaceutical company. Shire plc strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.

DEAL STATS #
Overall 15 of 16
Sector (Life Science) 15 of 15
Type (Merger) 2 of 2
State (Illinois) 1 of 1
Country (United States) 13 of 13
Year (2016) 1 of 1
Size (of disclosed) 1 of 12
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-11-02 Dyax

Burlington, Massachusetts, United States

Dyax is a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company is developing DX-2930, a fully human monoclonal antibody, for the prevention of HAE attacks. Additionally, Dyax markets KALBITOR® (ecallantide) for the treatment of acute attacks of HAE in patients 12 years of age and older.

Buy $5.9B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-07-20 Shire - Pre-clinical Programmes

Ireland

Shire Plc - Pre-clinical Programmes is a provider of targeting Central Nervous System (CNS) diseases. Pre-clinical Programmes includes Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Fatigue, and Addictive Behaviours.

Sell -
Mergr

Product

Company

Legal